LabCorp Offering Veridex's CTC Test for Clinical Trials Research in China | GenomeWeb

NEW YORK (GenomeWeb News) – Veridex announced this week a deal with Laboratory Corporation of America to make its CellSearch circulating tumor cell test available in China.

LabCorp's Beijing central laboratory is now the first clinical reference laboratory in the country to offer CTC testing and will offer the test to researchers conducting clinical trials.

The agreement follows regulatory approval in China last month for the test.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: new chromatin imaging approach, and more.

University of Wisconsin researchers uncover a mutation linked to Mauriac syndrome, which affects some children with type 1 diabetes.

Theranos has hired executives to oversee compliance and regulatory issues, the Wall Street Journal reports.

Chinese researchers to embark on a trial using a CRISPR/Cas9-based immunotherapy next month, Nature News reports.